{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=DNA+Damage&page=2", "query": { "condition": "DNA Damage", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=DNA+Damage&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-05-22T09:24:19.648Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03875313", "title": "Study of CB-839 (Telaglenastat) in Combination With Talazoparib in Patients With Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Solid Tumor", "Clear Cell Renal Cell Carcinoma", "TNBC - Triple-Negative Breast Cancer", "Colorectal Cancer", "CRC", "RCC", "ccRCC" ], "interventions": [ { "name": "CB-839", "type": "DRUG" }, { "name": "Talazoparib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Calithera Biosciences, Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 33, "start_date": "2019-05-20", "completion_date": "2020-07-29", "has_results": true, "last_update_posted_date": "2022-02-17", "last_synced_at": "2026-05-22T09:24:19.648Z", "location_count": 9, "location_summary": "Birmingham, Alabama • Atlanta, Georgia • Iowa City, Iowa + 6 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Iowa City", "state": "Iowa" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03875313" }, { "nct_id": "NCT03263650", "title": "Study of Olaparib Maintenance Following Cabazitaxel-Carbo in Men With AVPC", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Prostate Cancer Aggressiveness", "Prostate Carcinoma" ], "interventions": [ { "name": "Cabazitaxel", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Prednisone 5Mg", "type": "DRUG" }, { "name": "Olaparib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 96, "start_date": "2017-10-03", "completion_date": "2026-06-30", "has_results": false, "last_update_posted_date": "2026-02-17", "last_synced_at": "2026-05-22T09:24:19.648Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03263650" }, { "nct_id": "NCT04019327", "title": "A Study of the Drugs Talazoparib and Temozolomide in Prostate Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Prostate Cancer", "Prostate Adenocarcinoma", "Prostate Neoplasm", "Prostate Cancer Metastatic", "Castration-resistant Prostate Cancer" ], "interventions": [ { "name": "Talazoparib", "type": "DRUG" }, { "name": "Temozolomide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 16, "start_date": "2019-07-11", "completion_date": "2025-12-04", "has_results": false, "last_update_posted_date": "2025-12-15", "last_synced_at": "2026-05-22T09:24:19.648Z", "location_count": 9, "location_summary": "Basking Ridge, New Jersey • Montvale, New Jersey • Commack, New York + 6 more", "locations": [ { "city": "Basking Ridge", "state": "New Jersey" }, { "city": "Montvale", "state": "New Jersey" }, { "city": "Commack", "state": "New York" }, { "city": "Harrison", "state": "New York" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT04019327" }, { "nct_id": "NCT03554473", "title": "M7824 and Topotecan or Temozolomide in Relapsed Small Cell Lung Cancers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Carcinoma, Small Cell", "Lung Cancer", "Small Cell Lung Cancer" ], "interventions": [ { "name": "M7824", "type": "DRUG" }, { "name": "Topotecan", "type": "DRUG" }, { "name": "Temozolomide", "type": "DRUG" }, { "name": "EKG", "type": "DIAGNOSTIC_TEST" }, { "name": "CT scan", "type": "DIAGNOSTIC_TEST" }, { "name": "PET scan", "type": "DIAGNOSTIC_TEST" }, { "name": "Acetaminophen", "type": "DRUG" }, { "name": "Antihistamines", "type": "DRUG" }, { "name": "Diphenhydramine", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Epinephrine", "type": "DRUG" } ], "intervention_types": [ "DRUG", "DIAGNOSTIC_TEST" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 37, "start_date": "2018-09-11", "completion_date": "2025-03-13", "has_results": true, "last_update_posted_date": "2025-05-09", "last_synced_at": "2026-05-22T09:24:19.648Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT03554473" }, { "nct_id": "NCT02922790", "title": "Feasibility and Smokers' Reactions to DNA Feedback", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Smoking" ], "interventions": [ { "name": "standard health information", "type": "BEHAVIORAL" }, { "name": "standard health information plus info. on DNA damage", "type": "BEHAVIORAL" }, { "name": "Subjects will review standard health information and information on DNA damage, plus pictures of their DNA damage", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "Duke University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 39, "start_date": "2017-02-14", "completion_date": "2017-07-24", "has_results": false, "last_update_posted_date": "2018-01-05", "last_synced_at": "2026-05-22T09:24:19.648Z", "location_count": 1, "location_summary": "Durham, North Carolina", "locations": [ { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT02922790" }, { "nct_id": "NCT04030559", "title": "Niraparib Before Surgery in Treating Patients With High Risk Localized Prostate Cancer and DNA Damage Response Defects", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "ATM Gene Mutation", "BRCA1 Gene Mutation", "BRCA2 Gene Mutation", "BRIP1 Gene Mutation", "CDK12 Gene Mutation", "CHEK1 Gene Mutation", "CHEK2 Gene Mutation", "DNA Damage Response Gene Mutation", "DNA Repair Gene Mutation", "FANCA Gene Mutation", "FANCD2 Gene Mutation", "FANCL Gene Mutation", "GEN1 Gene Mutation", "NBN Gene Mutation", "Prostate Carcinoma", "RAD51 Gene Mutation", "RAD51C Gene Mutation" ], "interventions": [ { "name": "Niraparib", "type": "DRUG" }, { "name": "Niraparib Tosylate Monohydrate", "type": "DRUG" }, { "name": "Radical Prostatectomy", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "University of California, Davis", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 11, "start_date": "2020-02-25", "completion_date": "2025-11-07", "has_results": true, "last_update_posted_date": "2026-05-14", "last_synced_at": "2026-05-22T09:24:19.648Z", "location_count": 1, "location_summary": "Sacramento, California", "locations": [ { "city": "Sacramento", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04030559" }, { "nct_id": "NCT00553189", "title": "Safety Study of ABT-888 Plus Topotecan Hydrochloride to Treat Patients With Solid Tumors and Lymphomas", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumors", "Lymphomas" ], "interventions": [ { "name": "ABT-888", "type": "DRUG" }, { "name": "Topotecan", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 31, "start_date": "2007-08-09", "completion_date": "2011-09-28", "has_results": false, "last_update_posted_date": "2017-07-02", "last_synced_at": "2026-05-22T09:24:19.648Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00553189" }, { "nct_id": "NCT04126070", "title": "Nivolumab + Docetaxel + ADT in mHSPC Patients With DDRD or Inflamed Tumors", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hormone Sensitive Prostate Cancer", "Prostate Adenocarcinoma", "Metastasis Prostate Adenocarcinoma" ], "interventions": [ { "name": "Androgen Deprivation Therapy", "type": "DRUG" }, { "name": "Nivolumab", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Xiao X. Wei, MD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 60, "start_date": "2020-05-11", "completion_date": "2026-06-30", "has_results": false, "last_update_posted_date": "2026-01-22", "last_synced_at": "2026-05-22T09:24:19.648Z", "location_count": 6, "location_summary": "La Jolla, California • Tampa, Florida • Baltimore, Maryland + 2 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Tampa", "state": "Florida" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT04126070" }, { "nct_id": "NCT01306032", "title": "Phase II ABT-888 With Cyclophosphamide", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Ovarian Cancer", "Primary Peritoneal Cancer", "Serous Carcinoma Cancer", "Triple-Negative Breast Cancer", "Fallopian Tube Cancer" ], "interventions": [ { "name": "ABT-888", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 124, "start_date": "2011-01-12", "completion_date": "2016-12-15", "has_results": true, "last_update_posted_date": "2017-04-26", "last_synced_at": "2026-05-22T09:24:19.648Z", "location_count": 9, "location_summary": "Davis, California • Tampa, Florida • Chicago, Illinois + 6 more", "locations": [ { "city": "Davis", "state": "California" }, { "city": "Tampa", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Bethesda", "state": "Maryland" }, { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT01306032" }, { "nct_id": "NCT00340743", "title": "Diet and Genetic Damage", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Diet" ], "interventions": [], "intervention_types": [], "sponsor": "National Institute of Environmental Health Sciences (NIEHS)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "45 Years", "sex": "ALL", "summary": "18 Years to 45 Years" }, "enrollment_count": 16, "start_date": "2004-04-21", "completion_date": "2019-07-16", "has_results": false, "last_update_posted_date": "2019-07-18", "last_synced_at": "2026-05-22T09:24:19.648Z", "location_count": 1, "location_summary": "Chapel Hill, North Carolina", "locations": [ { "city": "Chapel Hill", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT00340743" } ] }